CDK6 was predicted to be a target of both the up regulated miR-34a-5p and the down regulated miR-449a, indicating regulation of cell cycle is central to APE and uPA treatment potentially works via cell cycle regulation. The gene discussed is CDK6; the disease is apparent mineralocorticoid excess.